Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT00253435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00253435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2013
Enrollment
50 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma